These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differential effects of horse ATG and rabbit ATG on T cell and T cell subset levels measured by monoclonal antibodies. Thomas FT; Griesedieck C; Thomas J; Carver M; Whitley T; Warren R; Williams D Transplant Proc; 1984 Dec; 16(6):1561-3. PubMed ID: 6239426 [No Abstract] [Full Text] [Related]
4. Studies on the activity of antithymocyte serum (ATS), particularly on the relation between its anti-inflammatory and immunosuppressive effects. Gieldanowski J; Blaszczyk B; Szymaniec S; Ludwikowska A Arch Immunol Ther Exp (Warsz); 1977; 25(3):367-75. PubMed ID: 329800 [TBL] [Abstract][Full Text] [Related]
9. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation. van Son WJ; van den Berg AP; The TH; Tegzess AM Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873 [No Abstract] [Full Text] [Related]
11. Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients. Ozaki KS; Câmara NO; Galante NZ; Camargo LF; Pacheco-Silva A Int Immunopharmacol; 2005 Jan; 5(1):103-6. PubMed ID: 15589467 [TBL] [Abstract][Full Text] [Related]
12. Immunologic monitoring of antithymocyte globulin treatment for acute allograft rejection. Delmonico FL; Nelson PW; Colvin RB; Cosimi AB Transplant Proc; 1984 Dec; 16(6):1492-3. PubMed ID: 6390852 [No Abstract] [Full Text] [Related]
13. Excellent renal allograft survival in donor-specific antibody transplant patients--role of intravenous immunoglobulin and rabbit antithymocyte globulin. Dhanda R; Shah Y; Bardapure M; Bhattacharjya S; Sharma AK Transplantation; 2009 Aug; 88(3):444. PubMed ID: 19667954 [No Abstract] [Full Text] [Related]
14. Superiority of soluble antigen extracts and antithymocyte globulin over whole blood and cytotoxic agents in inducing experimental allograft prolongation. Thomas F; Burke S; Thomas J; Lee HM; Lower RR Transplant Proc; 1979 Jun; 11(2):1442-3. PubMed ID: 382535 [No Abstract] [Full Text] [Related]
15. Pancreas transplant outcome with or without biological anti-T-cell therapy for induction immunosuppression with use of cyclosporine. Sutherland DE; Moudry-Munns KC; Gruessner A Transplant Proc; 1994 Oct; 26(5):2752-5. PubMed ID: 7940866 [No Abstract] [Full Text] [Related]
16. Kidney graft survival: role of blood transfusions and lymphocytotoxic antibodies. Fradet Y; Roy R; Lachance JG; Noël R Clin Nephrol; 1982 Aug; 18(2):69-73. PubMed ID: 6754190 [TBL] [Abstract][Full Text] [Related]
17. Combined pancreas-kidney transplants using quadruple immunosuppression therapy: a comparison between antilymphoblast and antithymocyte globulins. Fasola CG; Hricik DE; Schulak JA Transplant Proc; 1995 Dec; 27(6):3135-6. PubMed ID: 8539880 [No Abstract] [Full Text] [Related]
18. Posttransplant TLI is effective in nonhuman primates if combined with rabbit ATG. Carver M; Alqaisi M; Cunningham P; Gross U; Thomas F; Thomas J Transplant Proc; 1991 Feb; 23(1 Pt 1):480-2. PubMed ID: 1899310 [No Abstract] [Full Text] [Related]
19. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts. Alamartine E; Bellakoul R; Berthoux F Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975 [No Abstract] [Full Text] [Related]